AIMS: We studied the association between either non-selective NSAIDs (ns-NSAIDs), selective COX-2 inhibitors, or any NSAID and risk of incident myocardial infarction (MI) and heart failure (HF), and all-cause mortality in elderly subjects. METHODS: We conducted a retrospective nested case-control study on Australian veterans using nationwide hospital admission and pharmacy dispensing data. We estimated adjusted odds ratios (OR) with 95% confidence intervals (CI) for the risk of events for three different measures of prescription supply exposure over the last 2 years: (i) supplied at least once, (ii) supply frequency: supplied more than twice within the last 30 days, once or twice within the last 30 days, and once or more 30 days to 2 years and (iii) total supplies. RESULTS: We identified 83 623 cases and 1 662 099 matched controls (1:20) contributing 3 862 931 persons-years of observation. NSAID use at least once within the last 2 years did not significantly affect the risk of MI (OR 1.00, 95% CI 0.96, 1.04) but was associated with a mildly reduced risk of HF (OR 0.95, 95% CI 0.92, 0.98). There was a reduced all-cause mortality with at least one supply of either ns-NSAIDs (OR 0.94, 95% CI 0.90, 0.97), selective COX-2 inhibitors (OR 0.90, 95% CI 0.88, 0.93), or any NSAID (OR 0.87, 95% CI 0.85, 0.90). Risk of death was also inversely associated with the number of prescription supplies. CONCLUSIONS: NSAID use is not associated with an increased risk of incident MI and HF but is associated with a reduction in all-cause mortality in Australian veterans.
AIMS: We studied the association between either non-selective NSAIDs (ns-NSAIDs), selective COX-2 inhibitors, or any NSAID and risk of incident myocardial infarction (MI) and heart failure (HF), and all-cause mortality in elderly subjects. METHODS: We conducted a retrospective nested case-control study on Australian veterans using nationwide hospital admission and pharmacy dispensing data. We estimated adjusted odds ratios (OR) with 95% confidence intervals (CI) for the risk of events for three different measures of prescription supply exposure over the last 2 years: (i) supplied at least once, (ii) supply frequency: supplied more than twice within the last 30 days, once or twice within the last 30 days, and once or more 30 days to 2 years and (iii) total supplies. RESULTS: We identified 83 623 cases and 1 662 099 matched controls (1:20) contributing 3 862 931 persons-years of observation. NSAID use at least once within the last 2 years did not significantly affect the risk of MI (OR 1.00, 95% CI 0.96, 1.04) but was associated with a mildly reduced risk of HF (OR 0.95, 95% CI 0.92, 0.98). There was a reduced all-cause mortality with at least one supply of either ns-NSAIDs (OR 0.94, 95% CI 0.90, 0.97), selective COX-2 inhibitors (OR 0.90, 95% CI 0.88, 0.93), or any NSAID (OR 0.87, 95% CI 0.85, 0.90). Risk of death was also inversely associated with the number of prescription supplies. CONCLUSIONS: NSAID use is not associated with an increased risk of incident MI and HF but is associated with a reduction in all-cause mortality in Australian veterans.
Authors: Daniel H Solomon; Robert J Glynn; Kenneth J Rothman; Sebastian Schneeweiss; Soko Setoguchi; Helen Mogun; Jerry Avorn; Til Stürmer Journal: Arthritis Rheum Date: 2008-08-15
Authors: Emil Loldrup Fosbøl; Gunnar H Gislason; Søren Jacobsen; Steen Z Abildstrom; Morten Lock Hansen; Tina Ken Schramm; Fredrik Folke; Rikke Sørensen; Jeppe N Rasmussen; Lars Køber; Mette Madsen; Christian Torp-Pedersen Journal: Pharmacoepidemiol Drug Saf Date: 2008-08 Impact factor: 2.890
Authors: Eric S Williams; Sanjiv J Shah; Sadia Ali; Bee Ya Na; Nelson B Schiller; Mary A Whooley Journal: Eur J Heart Fail Date: 2007-12-21 Impact factor: 15.534
Authors: Aditya Bardia; Jon O Ebbert; Robert A Vierkant; Paul J Limburg; Kristin Anderson; Alice H Wang; Janet E Olson; Celine M Vachon; James R Cerhan Journal: J Natl Cancer Inst Date: 2007-06-06 Impact factor: 13.506
Authors: Stephen J Kerr; Debra S Rowett; Geoffrey P Sayer; Susan D Whicker; Deborah C Saltman; Andrea Mant Journal: Br J Clin Pharmacol Date: 2010-05-06 Impact factor: 4.335
Authors: Sheena Derry; Philip J Wiffen; R Andrew Moore; Ewan D McNicol; Rae F Bell; Daniel B Carr; Mairead McIntyre; Bee Wee Journal: Cochrane Database Syst Rev Date: 2017-07-12
Authors: Sheena Derry; Philip J Wiffen; Winfried Häuser; Martin Mücke; Thomas Rudolf Tölle; Rae F Bell; R Andrew Moore Journal: Cochrane Database Syst Rev Date: 2017-03-27
Authors: Patrick B Ryan; Martijn J Schuemie; Emily Welebob; Jon Duke; Sarah Valentine; Abraham G Hartzema Journal: Drug Saf Date: 2013-10 Impact factor: 5.606